Barcelona, Spain: In a series of experiments, researchers have found that an experimental MYC inhibitor drug not only targets lung cancer cells directly but also makes cancer cells easier for the immune system to target and kill.
MYC is a protein that is known to malfunction in cancer, allowing cells to grow and divide uncontrollably. However, until recently, researchers have struggled to find a way to target MYC.
The experimental drug OMO-103 was designed to inhibit MYC and is already being tested with patients in clinical trials. The new research, to be presented on Friday at the 38th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, shows that OMO-103 also seems to enable white blood cells to find and destroy cancer cells.
The research was presented by Laura Soucek, ICREA Research Professor, Director of the Experimental Therapeutics Research Program and Head of the Models of Cancer Therapies Laboratory at the Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, and co-founder and Chief Scientific Officer of Peptomyc S.L.
Professor Soucek said: "In this study we're looking at non-small cell lung cancer, which accounts for approximately 85% of lung cancers. Treatment for this type of cancer has changed substantially with the introduction of several new types of drugs. However, resistance remains a major problem: for many patients, their cancer does not respond to these treatments from the outset, and many cancers that initially respond eventually develop resistance.
"Our interest was in MYC, a protein that is well known for its ability to drive tumour cell proliferation, but it also helps tumours escape the immune system. We wanted to understand how the immune system behaves in and around a tumour when MYC is inhibited with a drug and whether it could help us to treat this type of cancer more effectively."
The researchers began by working with tumours samples taken from patients with non-small cell lung cancer. These cells had a fault in a gene called KRAS, which is known to activate MYC. When researchers treated the samples with OMO-103 in the lab, they saw white blood cells called CD4+ and CD8+ T cells entering the tumour tissue and signs that these blood cells were activating an immune response to the cancer cells.
Professor Soucek added: "When we experimentally removed T cells, OMO-103 still inhibited tumour growth, confirming its direct effect on cancer cells, but its efficacy was reduced by roughly half. This tells us that the immune response makes an important contribution to the full therapeutic effect of MYC inhibition."
The researchers also looked at how the drug was working by studying tumour samples and blood samples taken from patients who were being treated with OMO-103 in the MYCure phase I trial [2], including those with pancreatic, bowel and non-small cell lung cancer.
Professor Soucek explained their findings: "Patients who experienced clinical benefit in the trial showed activation of two immune system processes, interferon and the TNF-superfamily, whereas these changes were not detected in patients whose disease progressed. The TNF superfamily regulates many aspects of immune cell behaviour, for example it can help T cells survive, proliferate and sustain an effective immune response.
"But because we are looking at a small number of clinical samples, these observations should be considered exploratory."
Finally, the researchers studied the effects of the drug in mouse models of lung cancer. They found that combining OMO-103 with other drugs that help to activate an immune response to cancer increased its effectiveness. Combining OMO-103 with a drug that activates an immune-system protein called OX40 increased the objective response rate from 37% to 89%. Combining OMO-103 with a drug that activates another immune-system protein called 4-1BB increased the objective response rate from 29% to 100%, including two of seven animals where the tumour disappeared.
"These are preclinical results and should not be interpreted as expected response rates in patients, but they provide strong proof of concept for testing these combinations further," Professor Soucek added.
She continued: "One of the main strengths of this research is that we approached the same biological question from several complementary directions. The fact that related immune changes emerged across these different settings gives us greater confidence in their biological relevance.
"We will still need to carry out more experiments including prospective clinical testing. The ultimate goal is to evaluate rational combinations of MYC inhibition with immunotherapies in the clinic. We are particularly interested in determining which patients are most likely to benefit and whether the immune changes identified here, including activation of TNF-superfamily pathways, could serve as biomarkers of response."
Professor Ryan B. Corcoran is AACR Co-chair of the ENA Symposium, based at Harvard Medical School, USA, and was not involved in the research. He said: "These data suggest that a MYC inhibitor may work against cancer cells in two important ways. First, the inhibitor may work directly on cancer cells to slow their growth, but second the inhibitor may also help the immune system find and destroy tumour cells. These results provide an important basis for future patient trials combining a MYC inhibitor with other treatments designed to help the body's immune response to cancer cells."